Ken Griffin Allakos Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.0 - $1.45 $1,400 - $2,030	-1,400 Reduced 50.0%	1,400 $1,000
Q1 2024 May 15, 2024	SELL	$1.02 - $3.23 $5,508 - $17,442	-5,400 Reduced 65.85%	2,800 $3,000
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.18 $3,268 - $6,042	1,900 Added 30.16%	8,200 $22,000
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $13,206 - $34,410	6,200 Added 6200.0%	6,300 $14,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $41,760 - $60,900	-11,600 Reduced 99.15%	100 $0
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $47,730 - $91,797	11,100 Added 1850.0%	11,700 $52,000
Q4 2022 Feb 14, 2023	SELL	$5.66 - $8.42 $90,560 - $134,720	-16,000 Reduced 96.39%	600 $5,000
Q3 2022 Nov 14, 2022	SELL	$3.02 - $6.12 $17,818 - $36,108	-5,900 Reduced 26.22%	16,600 $102,000

104

70.7M

43.8K

1.4K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $54.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.